Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind very-low-dose controlled trial of ZY-A002 in children with cough variant asthma
CTR20261088Phase 3Active
- Sponsor
- Yabao Pharmaceutical Group Co., Ltd.
- Start
- May 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ZY-A002 in cough variant asthma (CVA) (2 arms), sponsored by Yabao Pharmaceutical Group Co., Ltd. Primary endpoint: Cough disappearance rate at Day 14. Started May 2026; status: active.
02
Drugs
ZY-A002
03
Conditions
cough variant asthma (CVA)
Beyond the preview
Go deeper on CTR20261088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261088.